Pembrolizumab in PD-L1–Positive Advanced Cervical Cancer

Get Permission

Jean-Sebastien Frenel, MD

Jean-Sebastien Frenel, MD

As reported in the Journal of Clinical Oncology by Jean-Sebastien Frenel, MD, of the Institut de Cancerologie de l’Ouest, Centre Rene Gauducheau, Saint-Herblain, France, and colleagues, pembrolizumab (Keytruda) treatment was found to be active in patients with programmed cell death ligand 1 (PD-L1)–positive advanced cervical cancer in the phase Ib KEYNOTE-028 trial.

Study Details

In the advanced cervical cancer cohort of the trial, 24 patients received pembrolizumab at 10 mg/kg every 2 weeks for up to 24 months. Response according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 was assessed every 8 weeks for the first 6 months and every 12 weeks thereafter. The primary endpoint was overall response rate. 

[R]esults from this analysis of the phase Ib KEYNOTE-028 trial suggest that pembrolizumab is well tolerated and has durable antitumor activity in patients with PD-L1–positive advanced cervical cancer.
— Jean-Sebastien Frenel, MD and colleagues

Tweet this quote

Patients had a median age of 42 years (range = 26–62 years), 92% had received prior radiation therapy, and 63% had received ≥ 2 lines of therapy for advanced disease, including bevacizumab (Avastin) in 42%. All patients had metastatic disease, including disease in the lymph nodes (n = 16; 67%), lung (n = 9; 38%), pelvis (n = 9; 38%), and liver (n = 6; 25%). PD-L1 positivity was defined as membranous staining ≥ 1%; 18 patients were PD-L1–positive in the tumor only, and 6 were PD-L1–positive in the tumor and stroma.

Response and Survival

At data cutoff, median follow-up was 11.0 months (range = 1.3–32.2 months). A partial response was observed in four patients (17%), with an additional three patients (13%) having stable disease. Median time to response was 1.9 months (range = 1.7–8.2 months).Median duration of response was 5.4 months (range = 4.1–7.5 months), with 2 patients having a response > 6 months. 

One patient had a response at a previously irradiated site. A decrease in the sum of diameters of target lesions was observed in 8 (36%) of 22 evaluable patients on computed tomography. All 4 responders had PD-L1 expression on the tumor only. 

Median progression-free survival was 2 months, with rates of 21% and 4% at 6 and 12 months. Median overall survival was 11 months, with rates of 67% and 40% at 6 and 12 months. 

Adverse Events

Treatment-related adverse events of any grade occurred in 75% of patients, with the most common being rash (21%) and pyrexia (17%). Treatment-related grade ≥ 3 adverse events occurred in 5 patients (21%, all grade 3), with rash occurring in 8%. Treatment-related serious adverse events occurred in four patients (17%), including one case each of rash, colitis, Guillain-Barré syndrome, and pyrexia. 


  • A response was observed in 17% of pembrolizumab recipients.
  • Two patients had a response > 6 months. 

Immune-mediated adverse events occurred in six patients (25%), including rash in two, colitis in one, Guillain-Barré syndrome in one, hyperthyroidism in one, and hypothyroidism in one. Treatment was discontinued due to treatment-related adverse events in two patients (8%), consisting of colitis and Guillain-Barré syndrome. No treatment-related deaths were observed. 

The investigators concluded: “[R]esults from this analysis of the phase Ib KEYNOTE-028 trial suggest that pembrolizumab is well tolerated and has durable antitumor activity in patients with PD-L1–positive advanced cervical cancer. The safety and clinical benefit of pembrolizumab in advanced cervical cancer are currently under investigation in the open-label, phase II, multicohort KEYNOTE-158 trial.” ■

DISCLOSURE: The study was funded by Merck & Co, Inc. For full disclosures of the study authors, visit


1. Frenel J-S, Le Tourneau C, O’Neil B, et al: Safety and efficacy of pembrolizu-mab in advanced, programmed death ligand 1–positive cervical cancer: Results from the phase Ib KEYNOTE-028 trial. J Clin Oncol. November 2, 2017 (early release online).

Related Articles

Checkpoint Inhibition for Patients With Recurrent or Advanced Cervical Cancer: A Promising Strategy, but Which Patients Will Benefit the Most?

Julia Fehniger, MD

Julia Fehniger, MD

Franco Muggia, MD

Franco Muggia, MD

For nearly 20 years, chemoradiation using single-agent platinum therapy has been the standard of care for advanced or recurrent cervical cancer.1 More recently, the Gynecologic Oncology Group (GOG) 240 trial tested the addition of bevacizumab...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.